A. T. Tuğlular Et Al. , "Post-Authorization Safety of Lenalidomide + Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma in Turkey," CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA , vol.15, pp.301-302, 2015
Tuğlular, A. T. Et Al. 2015. Post-Authorization Safety of Lenalidomide + Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma in Turkey. CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA , vol.15 , 301-302.
Tuğlular, A. T., Pehlivan, M., Sarı, İ., Ayyıldız, O., Saydam, G., Beşışık, S., ... Özgür, G.(2015). Post-Authorization Safety of Lenalidomide + Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma in Turkey. CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA , vol.15, 301-302.
Tuğlular, Ayşe Et Al. "Post-Authorization Safety of Lenalidomide + Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma in Turkey," CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA , vol.15, 301-302, 2015
Tuğlular, Ayşe T. Et Al. "Post-Authorization Safety of Lenalidomide + Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma in Turkey." CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA , vol.15, pp.301-302, 2015
Tuğlular, A. T. Et Al. (2015) . "Post-Authorization Safety of Lenalidomide + Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma in Turkey." CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA , vol.15, pp.301-302.
@article{article, author={Ayşe Tülin Tuğlular Et Al. }, title={Post-Authorization Safety of Lenalidomide + Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma in Turkey}, journal={CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA}, year=2015, pages={301-302} }